Development of purine-scaffold small molecule inhibitors of Hsp90.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Current Cancer Drug Targets

• Publication date

  2003-09-30

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.2174/1568009033481778PMID 14529388
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent

  2004cited by this paper
• 17AAG: low target binding affinity and potent cell activity--finding an explanation.

  2003cited by this paper
• Hsp90 inhibitors as novel cancer chemotherapeutic agents.

  2002cited by this paper
• Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase.

  2002cited by this paper
• HSP90 as a new therapeutic target for cancer therapy: the story unfolds

  2002cited by this paper
• A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells.

  2001cited by this paper
• Facile synthesis of a library of 9-alkyl-8-benzyl-9H-purin-6-ylamine derivatives.

  2001cited by this paper
• Stereospecific antitumor activity of radicicol oxime derivatives

  2001cited by this paper
• A Radicicol Derivative, KF58333, Inhibits Expression of Hypoxia‐inducible Factor‐1α and Vascular Endothelial Growth Factor, Angiogenesis and Growth of Human Breast Cancer Xenografts

  2001cited by this paper
• The hsp90-related Protein TRAP1 Is a Mitochondrial Protein with Distinct Functional Properties*

  2000cited by this paper
• Radicicol Binds and Inhibits Mammalian ATP Citrate Lyase*

  2000cited by this paper
• Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex.

  2000cited by this paper
• GHKL, an emergent ATPase/kinase superfamily.

  2000cited by this paper
• DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90.

  1999cited by this paper
• KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules.

  1999cited by this paper
• Hsp90 & Co. - a holding for folding.

  1999cited by this paper
• Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin.

  1999cited by this paper
• GRP94, an ER chaperone with protein and peptide binding properties.

  1999cited by this paper
• In Vivo Function of Hsp90 Is Dependent on ATP Binding and ATP Hydrolysis

  1998cited by this paper
• The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin

  1998cited by this paper
• The Hsp90 complex--a super-chaperone machine as a novel drug target.

  1998cited by this paper
• ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo

  1998cited by this paper
• Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin.

  1998cited by this paper
• A molecular clamp in the crystal structure of the N-terminal domain of the yeast Hsp90 chaperone

  1997cited by this paper
• Positionally cloned human disease genes: patterns of evolutionary conservation and functional motifs.

  1997cited by this paper
• Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent.

  1997cited by this paper
• Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone.

  1997cited by this paper
• An atypical topoisomerase II from archaea with implications for meiotic recombination

  1997cited by this paper
• Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives.

  1995cited by this paper
• erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships.

  1995cited by this paper
• Nucleotide sequence of a full-length cDNA for 90 kDa heat-shock protein from human peripheral blood lymphocytes.

  1989cited by this paper
• Irreversible inhibition of v-src tyrosine kinase activity by herbimycin A and its abrogation by sulfhydryl compounds.

  1989cited by this paper
• Nucleotide sequence of a cDNA for a member of the human 90-kDa heat-shock protein family.

  1987cited by this paper

• In Silico Design of Dual Estrogen Receptor and Hsp90 Inhibitors for ER-Positive Breast Cancer Through a Mixed Ligand/Structure-Based Approach

  2024influential citation
• Previously unrecognized and potentially consequential challenges facing Hsp90 inhibitors in cancer clinical trials

  2024cites this paper
• The Distinct Assignments for Hsp90α and Hsp90β: More Than Skin Deep

  2023cites this paper
• Some novel peptides containing a modified pyrazolopyrimidine moiety: design, synthesis, and in vitro antibacterial screening

  2023cites this paper
• Scaffolds of Purine Privilege for Biological Cytotoxic Targets: A Review

  2023cites this paper
• Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications

  2022cites this paper
• Role of HSP90 in Cancer

  2021cites this paper
• Heterogeneous Responses and Isoform Compensation Dim the Therapeutic Window of Hsp90 ATP-Binding Inhibitors in Cancer

  2021cites this paper
• Total Synthesis of trans-Resorcylide via Macrocyclic Stille Carbonylation

  2019cites this paper
• EXPERT OPINION ON DRUG DISCOVERY INVITED REVIEW Induced degradation of protein kinases by bifunctional small molecules: a next-generation strategy Sole author:

  2019cites this paper
• Induced degradation of protein kinases by bifunctional small molecules: a next-generation strategy

  2019cites this paper
• Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development

  2018cites this paper
• In Vivo Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior

  2017cites this paper
• Discovery of Novel Allopurinol Derivatives with Anticancer Activity and Attenuated Xanthine Oxidase Inhibition

  2016cites this paper
• PU-H 71 : An improvement on nature ’ s solutions to oncogenic Hsp 90 addiction

  2015influential citation
• Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phase.

  2015cites this paper
• Novologue Therapy Improves Mitochondrial Bioenergetics and Modulates Transcriptome Changes in Diabetic Sensory Neurons

  2015cites this paper
• PU-H71: An improvement on nature's solutions to oncogenic Hsp90 addiction.

  2015cites this paper
• BIIB021, an Hsp90 inhibitor, effectively kills a myelodysplastic syndrome cell line via the activation of caspases and inhibition of PI3K/Akt and NF-κB pathway proteins

  2014cites this paper
• The novel HSP90 inhibitor, PU-H71, suppresses glial cell activation but weakly affects clinical signs of EAE.

  2013cites this paper
• The HSP90 inhibitor NVP‐AUY922‐AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells

  2013cites this paper
• Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies.

  2013cites this paper
• Cancer Therapy : Preclinical A Purine Scaffold HSP 90 Inhibitor BIIB 021 Has Selective Activity against KSHV-Associated Primary Effusion Lymphoma and Blocks vFLIP K 13-Induced NFk B

  2013cites this paper
• Tethered Hsp90 Inhibitors Carrying Optical or Radioiodinated Probes Reveal Selective Internalization of Ectopic Hsp90 in Malignant Breast Tumor Cells

  2013cites this paper
• Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells.

  2013cites this paper
• A 2,6,9-hetero-trisubstituted purine inhibitor exhibits potent biological effects against multiple myeloma cells.

  2013cites this paper
• A Purine Scaffold HSP90 Inhibitor BIIB021 Has Selective Activity against KSHV-Associated Primary Effusion Lymphoma and Blocks vFLIP K13-Induced NF-κB

  2013cites this paper
• Design, synthesis, and biological evaluation of novel deguelin-based heat shock protein 90 (HSP90) inhibitors targeting proliferation and angiogenesis.

  2012cites this paper
• Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects

  2012cites this paper
• Heat Shock Protein 90 and Role of Its Chemical Inhibitors in Treatment of Hematologic Malignancies

  2012cites this paper
• How well can fragments explore accessed chemical space? A case study from heat shock protein 90.

  2011cites this paper
• Conformational dynamics of the molecular chaperone Hsp90

  2011cites this paper
• Lead identification of β-lactam and related imine inhibitors of the molecular chaperone heat shock protein 90.

  2011cites this paper
• Synthesis and characterization of 9-methyl-2-morpholin-4-yl-8-substituted phenyl-1H-purine derivatives using polyphosphoric acid (PPA) as an efficient catalyst

  2011cites this paper
• Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation

  2011cites this paper
• A High-Throughput TNP-ATP Displacement Assay for Screening Inhibitors of ATP-Binding in Bacterial Histidine Kinases

  2011cites this paper
• Synthesis of (Glycopyranosyl‐triazolyl)‐purines and Their Inhibitory Activities against Protein Tyrosine Phosphatase 1B (PTP1B)

  2011cites this paper
• Clinical implications of cancer self-seeding

  2011cites this paper
• Hsp90 inhibitors and drugs from fragment and virtual screening.

  2011cites this paper
• Assessing the chemical diversity of an hsp90 database.

  2010cites this paper
• Nature as Source of Medicines; Novel Drugs from Nature; Screening for Antitumor Activity

  2010cites this paper
• Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma

  2009cites this paper
• Impact of natural products on developing new anti-cancer agents.

  2009cites this paper
• Grp94, the endoplasmic reticulum Hsp90, has a similar solution conformation to cytosolic Hsp90 in the absence of nucleotide

  2009cites this paper
• pH-dependent conformational changes in bacterial Hsp90 reveal a Grp94-like conformation at pH 6 that is highly active in suppression of citrate synthase aggregation.

  2009cites this paper
• A purine scaffold Hsp90 inhibitor destabilizes Bcl6 and has specific anti-tumor activity in Bcl6 dependent B-cell lymphomas

  2009cites this paper
• Cancer Therapy : Preclinical CUDC-305 , a Novel Synthetic HSP 90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy

  2009cites this paper
• CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy

  2009cites this paper
• CHAPERONE EXPRESSION AND EFFECTS OF ITS INHIBITION ON BREAST CANCER SENSITIZATION

  2009cites this paper
• Efficient Synthesis of a Novel Resorcyclide as Anticancer Agent Based on Hsp90 Inhibition.

  2008cites this paper
• Chapter 58 – Heat Shock Protein 90 and the Proteasome: Housekeeping Proteins Become Novel Molecular Targets for Cancer Therapy

  2008cites this paper
• Heat shock protein-90 directed therapeutics and target validation

  2008cites this paper
• The Hsp90 Family of Molecular Chaperones

  2008cites this paper
• Multiple conformations of E. coli Hsp90 in solution: insights into the conformational dynamics of Hsp90.

  2008cites this paper
• Molecular imaging of the efficacy of heat shock protein 90 inhibitors in living subjects.

  2008cites this paper
• A novel conformation of E. coli Hsp90 in solution: insights into the conformational dynamics of Hsp90

  2008cites this paper
• The Hsp90 inhibitor radicicol interacts with the ATP-binding pocket of bacterial sensor kinase PhoQ.

  2008cites this paper
• Synthetic and computational efforts toward the understanding and development of novobiocin-derived inhibitors of Hsp90

  2008cites this paper
• Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.

  2007cites this paper
• Geldanamycin promotes nuclear localisation and clearance of PHOX2B misfolded proteins containing polyalanine expansions.

  2007cites this paper
• In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors.

  2007cites this paper
• 1.08 – Natural Product Sources of Drugs: Plants, Microbes, Marine Organisms, and Animals

  2007cites this paper
• A duplexed phenotypic screen for the simultaneous detection of inhibitors of the molecular chaperone heat shock protein 90 and modulators of cellular acetylation

  2007cites this paper
• Targeting Hsp90 in Cancer and Neurodegenerative Disease

  2007cites this paper
• Recent Development in Novel Anticancer Therapies

  2007cites this paper
• DRUGGING THE HSP90 MOLECULAR CHAPERONE MACHINE FOR CANCER TREATMENT

  2007cites this paper
• Heat shock protein 90: The cancer chaperone

  2007cites this paper
• Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site.

  2006cites this paper
• Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.

  2006cites this paper
• Using natural product inhibitors to validate Hsp90 as a molecular target in cancer.

  2006cites this paper
• Structural Analysis of E. coli hsp90 reveals dramatic nucleotide-dependent conformational rearrangements.

  2006cites this paper
• Screening-based Discovery and Structural Dissection of a Novel Family 18 Chitinase Inhibitor*

  2006cites this paper
• Preclinical pharmacokinetics and metabolism of a novel diaryl pyrazole resorcinol series of heat shock protein 90 inhibitors

  2006cites this paper
• Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90.

  2006cites this paper
• Hsp90 inhibitors: Small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation

  2006cites this paper
• Thermoregulation in the life cycle of nematodes.

  2006cites this paper
• The purines: potent and versatile small molecule inhibitors and modulators of key biological targets.

  2006cites this paper
• Discovery and development of pyrazole-scaffold Hsp90 inhibitors.

  2006cites this paper
• Targeting chaperones in transformed systems – a focus on Hsp90 and cancer

  2006cites this paper
• Therapeutic aspects of chaperones/heat-shock proteins in neuro-oncology

  2006cites this paper
• A fluorescence polarization assay for inhibitors of Hsp90.

  2006cites this paper
• Triad3A Regulates Ubiquitination and Proteasomal Degradation of RIP1 following Disruption of Hsp90 Binding*

  2006cites this paper
• Orally active purine-based inhibitors of the heat shock protein 90.

  2006cites this paper
• Novel treatment strategies for aggressive non-Hodgkin’s lymphoma

  2006cites this paper
• Targeting the androgen receptor as a therapeutic strategy for prostate cancer.

  2006cites this paper
• A SURVEY OF NOVEL MOLECULAR TARGETS FOR ANTICANCER DRUG DISCOVERY

  2006cites this paper
• THE THERAPEUTIC PROMISE OF CANCER GENOMICS

  2006cites this paper
• The search for novel drug leads for predominately antitumor therapies by utilizing mother nature's pharmacophoric libraries.

  2005cites this paper
• BAG-1: a multi-functional pro-survival molecule.

  2005cites this paper
• Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics.

  2005cites this paper
• HSP90: a rising star on the horizon of anticancer targets.

  2005cites this paper
• Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.

  2005cites this paper
• Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90.

  2005cites this paper
• Design, synthesis, and biological evaluation of HSP90 inhibitors based on conformational analysis of radicicol and its analogues.

  2005cites this paper
• Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics – an update

  2005cites this paper
• Solution- and solid-phase synthesis of radicicol (monorden) and pochonin C.

  2005cites this paper
• Akt-regulated pathways in prostate cancer

  2005cites this paper
• AKT Kinase and Hsp90 Inhibitors as Novel Anti-cancer Therapeutics

  2005cites this paper
• Hsp90 is essential in the filarial nematode Brugia pahangi.

  2005cites this paper
• Heat shock protein 90 inhibitors. A text book example of medicinal chemistry?

  2005cites this paper